Reference is made to the stock exchange notice issued on 26 July 2019 by Hofseth Biocare ASA (the "Company") regarding the completion of a private placement raising gross proceeds of approximately NOK 118 million through issuance of 29,483,628 new shares at a subscription price of NOK 4 per share (the "Private Placement").
The following board members and primary insiders have been allocated shares in the Private Placement:
- Roger Hofseth AS, a 100% owned company of CEO Roger Hofseth, has today been allocated 3,750,000 shares in the Private Placement. Following completion of the Private Placement, Roger Hofseth AS will hold 51,389,998 shares in the Company, corresponding to 15.85 % of the total outstanding shares in the Company.
For further information, please contact:
Roger Hofseth, CEO of Hofseth BioCare ASA
Phone: +47 951 47 941
E-mail: rh@hofseth-as.no
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act